Proteo Announces Patient Recruitment and Treatment in Elafin CABG Phase II Clinical Trial Completed

Proteo

and its wholly-owned subsidiary Proteo Biotech AG today announced that the NHS Lothian's Edinburgh Heart Centre has successfully completed patient recruitment and treatment for the Phase II clinical trial (EMPIRE study) with Proteo's drug candidate Elafin for prevention of myocardial injury after coronary artery bypass surgery (CABG). According to plan top-line results from this trial are expected to be announced in the first quarter of 2014. The EMPIRE (Elafin Myocardial Protection from Ischaemia Reperfusion Injury) study is a placebo-controlled, double-blinded, Phase 2 clinical trial to investigate the efficacy and safety of Elafin in coronary bypass surgery which was started in the third quarter of 2011. The preoperative Elafin treatment